table td { font-size: 16px !important; }
NASH
11/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD
Read More
PRESS RELEASES
10/2020

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

San Mateo, California, October 6, 2020 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 in nonalcoholic steatohepatitis (NASH)…
Read More
Oncology
09/2020

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

European Society for Medical Oncology (ESMO) Congress
Read More
brain_imagination-2560x1440
NASH
08/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress
Read More
NASH
08/2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress
Read More
NASH
07/2020

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020
Read More
PRESS RELEASES
06/2020

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Oral FASN inhibitor TVB-2640 significantly reduces liver fat with a 61% responder rate Demonstrates improvement in markers of liver function and fibrosis Results to be presented on August 28 at…
Read More
PRESS RELEASES
03/2020

Data on Sagimet’s Lead Candidate TVB-2640 to be Presented at EASL ILC 2020

Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology…
Read More
Uncategorized
09/2019

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study

(Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)
Read More